ArticleFrontiers in cardiovascular medicine2025
Combining triglyceride glucose-body mass index and high-sensitivity C-reactive protein to predict cardiovascular disease: results from a national cohort and a clinical verified cohort.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-term high-sensitivity C-reactive protein trajectories and risk of major adverse cardiovascular events in statin-treated patients: a retrospective cohort.Cardiovascular diagnosis and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accumulating evidence highlights a strong association between insulin resistance (IR) and inflammation in the context of cardiovascular disease (CVD). However, the combined impact of both factors on the risk of developing CVD remains underexplored. This study aims to investigate how inflammation and insulin resistance interact to influence the risk of incident CVD. Methods: A total of 6,534 adults from the CHARLS were included. The primary endpoint was the occurrence of cardiovascular disease (CVD), defined as a composite of stroke and cardiac events. Participants were categorized according to the median values of two key markers: the triglyceride glucose-body mass index (TyG-BMI index) and high-sensitivity C-reactive protein (hsCRP). Cox proportional hazard models assessed the associations between TyG-BMI index, hsCRP, and the endpoints. To validate the reliability of the results, we clinically enrolled 805 patients who had undergone percutaneous coronary intervention (PCI). Results: In CHARLS, Multivariate Cox regression analysis revealed a significant association between elevated TyG-BMI index and hsCRP levels and an increased risk of CVD. Participants in the high TyG-BMI and high hsCRP group demonstrated a substantially higher risk of CVD (HR: 1.38, 95% CI: 1.18-1.62, Conclusion: These results emphasize the importance of simultaneously considering both TyG-BMI index and hsCRP levels in risk stratification for CVD, highlighting their combined potential to enhance early identification of high-risk individuals. Importantly, TyG-BMI also demonstrated significant predictive value for adverse outcomes in patients after PCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.